NA
CORT icon

NewEdge Advisors’s Corcept Therapeutics CORT Stock Holding History

NewEdge Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$377K Buy
9,364
+8,232
+727% +$308K ﹤0.01% 2184
2025
Q4 		$39.4K Sell
1,132
-4,819
-81% -$379K ﹤0.01% 3027
2025
Q3 		$495K Buy
5,951
+4,752
+396% +$344K ﹤0.01% 1824
2025
Q2 		$88K Sell
1,199
-3,337
-74% -$242K ﹤0.01% 2464
2025
Q1 		$518K Buy
+4,536
New +$276K ﹤0.01% 1568
2024
Q3 		– Sell
-562
Closed -$18.3K – 3838
2024
Q2 		$18.3K Buy
+562
New +$15.4K ﹤0.01% 2654
2024
Q1 		– Sell
-1,178
Closed -$38.3K – 3846
2023
Q4 		$38.3K Sell
1,178
-110
-9% -$3.02K ﹤0.01% 2314
2023
Q3 		$35.1K Sell
1,288
-33
-2% -$955 ﹤0.01% 2210
2023
Q2 		$29.4K Sell
1,321
-140
-10% -$3.22K ﹤0.01% 2268
2023
Q1 		$31.6K Sell
1,461
-7,319
-83% -$160K ﹤0.01% 2182
2022
Q4 		$138K Sell
8,780
-35,102
-80% -$880K ﹤0.01% 1315
2022
Q3 		$1.13M Buy
43,882
+9,145
+26% +$245K 0.02% 608
2022
Q2 		$826K Sell
34,737
-2,287
-6% -$49.8K 0.01% 756
2022
Q1 		$833K Buy
+37,024
New +$788K 0.01% 698

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

NewEdge Advisors's CORT Position: Q1 2026 in Review

NewEdge Advisors increased its Corcept Therapeutics (CORT) stake by 727% in Q1 2026, buying an estimated $308K and bringing the position to 9,364 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #2184.

NewEdge Advisors first reported a position in CORT in Q1 2022 and has held it in 14 quarters since. The position peaked at $1.13M in Q3 2022. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • NewEdge Advisors held 9,364 shares of Corcept Therapeutics worth $377K as of Q1 2026.
  • NewEdge Advisors bought 8,232 Corcept Therapeutics shares in Q1 2026, an estimated $308K.
  • Corcept Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2184 holding.
  • NewEdge Advisors first reported a position in Corcept Therapeutics in Q1 2022 and has held it in 14 quarters since.
  • NewEdge Advisors's Corcept Therapeutics position peaked at $1.13M in Q3 2022.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.